Central Nervous System Lymphoma

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of non-Hodgkin lymphoma that specifically targets the central nervous system (CNS), including the brain and spinal cord, or the vitreoretinal space. Alfa Cytology is committed to pioneering new therapeutic approaches for PCNSL treatment for our clients.

Overview of Central Nervous System Lymphoma

The incidence of PCNSL has been steadily increasing, particularly among immunocompromised patients, with a median age at diagnosis of 67 years. The unique pathophysiological mechanisms underlying PCNSL involve specific genetic alterations, including mutations in MYD88 and CD79B, which play crucial roles in the activation of oncogenic signaling pathways. Understanding these mechanisms is vital for the development of targeted therapies.

Fig.1 Primary central nervous system lymphoma high incidence and poor survival. (Puhakka I., et al., 2022)

Therapeutic Development for CNS Lymphoma

Despite the effectiveness of initial treatment regimens, which commonly include methotrexate-based chemotherapy combined with radiation therapy, high rates of relapse remain a significant challenge. This underscores the urgent need for innovative therapeutic strategies aimed at improving patient outcomes. Several promising targeted drugs have been developed and are currently being studied in the hope of finding novel therapeutic strategies to treat this pathology.

Our Services

At Alfa Cytology, we offer a comprehensive range of services designed to facilitate CNS lymphoma diagnostics and therapy development. Our team provides extensive support throughout the drug development process, from initial screening of compounds to detailed pharmacokinetic and pharmacodynamic studies.

Therapeutics Development

• Small Molecule Drug
• Radionuclide Therapy
• Therapeutic Antibody
• Peptide Drug
• Cell Therapy
• Gene Therapy
• Oncolytic Virotherapy
• Vaccine

Modeling Services

• Cell Line Development
• Organoids and Organ Chip Models
• Blood Brain Barrier Models
• Xenograft Models
• Syngeneic Models
• Virus-induced Models
• Transgenic Models
• Metastatic Models

Preclinical Research

• In Vitro Efficacy Evaluation
• In Vivo Efficacy Evaluation
• In Vitro ADME
• In Vivo PK
• Safety Assessment

Diagnostic Development

• Omics Analysis
• Cell Analysis
• Tissue Analysis
• Cytokine Analysis
• Chemokine Analysis
• Growth Factor Analysis
• Primary Immune Cell Analysis

Contact Us

For more information about our services or to discuss potential collaborations, please reach out to us at Alfa Cytology. Our dedicated team of biological experts is ready to assist you in advancing your research and therapeutic development efforts in CNS lymphoma.

Reference

1. Puhakka I.; et al. (2022). Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis[J]. BMC Cancer. 22, 236.